$MEDP

Medpace Holdings, Inc.

Medpace is a clinical contract research organization that provides outsourced clinical development services to biotechnology, pharmaceutical and medical device companies. It supports the development process across Phase I to Phase IV clinical trials and works across therapeutic areas, including oncology, metabolic, cardiology, antiviral and anti-infective, and central nervous system. Its customers include small, mid-sized and large pharmaceutical companies. Medpace earns money by providing clinical trial services such as study design and management, feasibility, start-up, patient recruitment, monitoring, regulatory affairs, medical writing, data science, pharmacovigilance and laboratory services. It also operates clinics for studies involving healthy volunteers and patient populations. Its ClinTrak system supports clinical trial management. Medpace is headquartered in Cincinnati, Ohio, where its clinical research campus and bioanalytical laboratory are located.

No enriched coverage for $MEDP in the last 7 days.

—
$14.4M
BURWIG SUSAN E
0%
See all $MEDP insider activity →

EWALD STEPHEN P sold $859K of MEDP

EWALD STEPHEN P (General Counsel & Corp. Secy.) sold 1,245 shares of Medpace Holdings, Inc. (MEDP) at $690.00 ($0.86M total) on 2026-10-29.

BURWIG SUSAN E sold $13.5M of MEDP

BURWIG SUSAN E (Exec. VP, Operations) sold 20,000 shares of Medpace Holdings, Inc. (MEDP) at $677.00 ($13.54M total) across 2 trades over 2026-10-26 to 2026-10-27.

MEDP sentiment & insider activity

Recent MEDP coverage spans financial news, earnings and insider activity.

In the last 30 days, MEDP insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($14.4M). The most active reporter was BURWIG SUSAN E, Exec. VP, Operations, with 2 filings.

What's driving MEDP

  • Medpace Holdings' General Counsel Stephen P. Ewald sold 1,245 shares at $690 each, totaling $859,050. He now directly owns 19,098 shares, according to an SEC Form 4 filing.

    tradingview.com · Nov 2, 2026

  • The insider sale may create modest downward pressure on MEDP as investors interpret the sell as a negative signal.

    SEC EDGAR · Nov 2, 2026

  • The insider sale may signal reduced confidence and could pressure the stock.

    SEC EDGAR · Oct 28, 2026

  • Strong earnings beat and raised guidance suggest upside potential.

    finance.yahoo.com · Oct 23, 2026

  • UBS raised its price target on Medpace to $700 from $673 while maintaining a neutral rating. The stock is currently trading at $666.52, up 1.92% today and 7.35% year-to-date. Truist Securities also adjusted its target to $633 from $609, keeping a hold rating.

    marketscreener.com · Oct 23, 2026

AlphAI scores every news story that mentions MEDP with an AI model for sentiment and relevance, and aggregates insider trades from Medpace Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MEDP

Score

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10Earnings

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

Medpace Holdings, Inc. (MEDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Investor Contact: David Ruhe 283-227-6472 d.ruhe@medpace.com FOR IMMEDIATE RELEASE Media Contact: Michael Maley 283-227-6367 m.maley@medpace.com Medpace Holdings, Inc. Reports Third Quarter 2026 Results • Revenue of $716.0 million in the third quarter of 2026 increas

$MEDPHighAI 8/10

Medpace in the spotlight: Can earnings sustain bookings momentum?

Medpace Holdings Inc. reports Q3 earnings with analysts expecting $4.44 EPS on $714.47M revenue, up from Q2. The company trades at $622.43 with a market cap of $17.4B. Analysts have a neutral consensus rating and a mean price target of $595.92. Investors will watch bookings momentum and backlog growth, which stood at $3.01B in Q2. Medpace's premium valuation and AI disruption are also key concerns.

Top insider buys and sells disclosed on Friday

Beyond Air (XAIR) director bought $56,590 in shares, Compass Therapeutics (CMPX) CFO acquired $18,400 in stock, Sky Harbour (SKYH) CFO purchased $15,040 in shares. CrowdStrike (CRWD) president sold $64M, Medpace (MEDP) CEO sold $30M, Snowflake (SNOW) director sold $17M. Insider trades may indicate confidence or tax obligations.

Related tickers